Aller au contenu principal

Postdoctoral Fellow in Development of a novel regulatory T cell therapy for type 1 diabetes - Fillatreau Lab

Institut Necker Enfants Malades (INEM) is a biomedical research center located on the Necker campus. It benefits from numerous state-of-the-art core facilities. The Campus has a long-standing reputation for scientific excellence and key pioneering medical contributions (transplantation, biotherapy, gene therapy). It provides a vibrant environment for basic research and translational innovation.

The host laboratory

The Immunity in Heath and Disease team, led by Simon Fillatreau, investigates the roles of B and T cells in autoimmune and infectious diseases, with a particular emphasis on identifying and characterizing novel pro-inflammatory and anti-inflammatory T cell, B cell and plasma cell subsets.

About the project

Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, caused by the autoimmune destruction of insulin-producing beta cells, yet the standard of care is insulin replacement, acting only at the symptom level. Thus, T1D is a disease with a high unmet need for innovative therapy. 

Our goal is to develop a cell-based therapy using TCR-engineered Tregs for cell therapy in T1D.

This project is funded via the European consortium ARTiDe coordinated by S. Fillatreau. ARTiDe involves 8 partners providing novel technologies for the systematic identification of autoantigen-specific Tregs and Teffs in humans, the selection of optimal TCR to produce protective Tregs, innovative humanized T1D pre-clinical models to test their efficacy and safety, the development of industrial process for TCR-engineered Treg production, and new Treg supporting strategies in vivo.

Your profile

Candidates must have a PhD and be highly motivated, self-driven, independent, and creative with strong organizational, writing, and communication skills. Fluency in English and the ability to work in a multicultural environment are essential.

This post-doctoral scientist will work on

1) the molecular characterization of autoreactive Teffs and Tregs at single cell level in patients with T1D and control in order to decipher the basis for the loss of immunological tolerance in this human disease,

2) the evaluation of the selected autoreactive TCR obtained through the single cell studies above for their capacity to produce protective Tregs using a novel humanized model for T1D. 

The position is funded for 3 years. Salary will be according to experience following INSERM regulation.

How to apply

Interested applicants should send: a cover letter describing their research background, motivation, and future interests, a Curriculum Vitae and contact information for three referees.

Please email applications to @email@email.

Applications will be reviewed upon submission and will remain open until the position is filled.